RECURSION PHARMACEUTICALS INC CLAS (RXRX)
Health Care · AI-enabled drug discovery and TechBio · NASDAQ
Recursion is a clinical-stage AI-native drug discovery platform that uses machine learning and biological datasets to rapidly identify and develop novel medicines.
What RECURSION PHARMACEUTICALS INC CLAS does
Recursion is a clinical-stage TechBio company that has developed an integrated AI-powered drug discovery and development platform called the Recursion Operating System (OS). The platform integrates multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development to accelerate the translation of biological insights into medicines. The company operates through a combination of internal pipeline development and strategic partnerships with major biopharmaceutical companies, having received over $500 million in milestone and collaboration payments to date.
Themes: ["AI-enabled drug discovery","TechBio / computational biology","Precision medicine","Clinical-stage drug development","Machine learning for therapeutics"]
Fundamentals
- Price$3.76 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return-32.7% as of 2026-07-09 close
- Net margin-842.9% as of 2026-07-10
- Gross margin+7.2% as of 2026-07-10
- ROE-54.3% as of 2026-07-10
- Debt / equity0.02 as of 2026-07-10
- Revenue growth (YoY)+11.1% as of 2026-07-10
- Revenue CAGR (3y)+23.3% SEC XBRL
- Beta1.07 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Exscientia
- Insilico Medicine
- Atomwise
- BenevolentAI
- Schrodinger (SDGR)
- Roche
- Genentech
- Sanofi
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.